Beta Bionics, Inc.
Close on Oct 19, 2026
- Market cap
- $750.14M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 27, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 29, 2026 | After market close | $32.00M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 21, 2026 | After market close | $27.60M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 17, 2026 | After market close | $32.10M | $-0.30 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 28, 2025 | After market close | $27.30M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 29, 2025 | After market close | $23.20M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $17.60M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 25, 2025 | After market close | $20.40M | – | – |
Company guidance
Outlook given with results on Jul 29, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| gross margin | 2026 Full Year | 58.5% to 59.5% | Raised |
| new patient starts reimbursed through the PBP channel | 2026 Full Year | 37% to 39% | Maintained |
| total revenue | 2026 Full Year | $131.00M to $136.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Beta Bionics filed with the SEC
Beta Bionics Announces Proposed Public Offering of $125.0 Million of Common Stock
Other events · EX-99.1 to Form 8-K
Beta Bionics Announces Pricing of Public Offering of Common Stock and
Other events · EX-99.2 to Form 8-K
Beta Bionics Announces FDA Clearance of Mint , the Company’s Transformative Patch Pump, and
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
Results of operations · EX-99.1 to Form 8-K
Beta Bionics Updates Commercialization Timeline Expectations for Mint, its Patch Pump in Development
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
Results of operations · EX-99.1 to Form 8-K
Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026
Results of operations · EX-99.1 to Form 8-K
Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics
Results of operations · EX-99.1 to Form 8-K
Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
Results of operations · EX-99.1 to Form 8-K
Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
Results of operations · EX-99.1 to Form 8-K
ADA Investor & Analyst Event June 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025
Results of operations · EX-99.1 to Form 8-K
Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025
Results of operations · EX-99.1 to Form 8-K
Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K